/
Oncology
Malignant Solid Tumors
60
Pipeline Programs↗
63
Active Trials↗
54
Companies Involved↗
Malignant Solid Tumors is a moderately active landscape with 60 programs across 54 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Cumberland Pharmaceuticals. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 117
Phase 229
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
37 of 54 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 93% of 60 pipeline programs.
Analysis
Trial Status
143
clinical trials
Recruiting44 · 31%
Completed36 · 25%
Unknown status27 · 19%
Terminated15 · 10%
Not yet recruiting12 · 8%
Active, not recruiting6 · 4%
Other3 · 2%
Clinical Trials
Trial Activity
143 trials
A Single-Arm, Open-Label, Dose-Escalation/Cohort-Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, PK/PD Profiles, and Preliminary Efficacy of TPD3310 Injection in Advanced Malignant Solid Tumor Patients
Recruiting·TTAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.·Phase 1·NCT07368127·112 enrolled
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Recruiting·—·Phase 1·NCT07348042·198 enrolled
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Recruiting·—·Phase 2·NCT07071103·48 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)